elhamkhani
/
Test2
/
Login
Register
TriplyDB
Test2
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q35501246-12617817-A7A6-4E35-9F22-0C9EBAAAD713
Q35501246-12617817-A7A6-4E35-9F22-0C9EBAAAD713
BestRank
Statement
http://www.wikidata.org/entity/statement/Q35501246-12617817-A7A6-4E35-9F22-0C9EBAAAD713
Chemotherapy and target therapy for hepatocellular carcinoma: New advances and challenges.
P2860
Q35501246-12617817-A7A6-4E35-9F22-0C9EBAAAD713
BestRank
Statement
http://www.wikidata.org/entity/statement/Q35501246-12617817-A7A6-4E35-9F22-0C9EBAAAD713
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
39b172419c5a31baa294485054ec87ffdb0985b6
P2860
Multicenter phase I trial of the mitogen-activated protein kinase 1/2 inhibitor BAY 86-9766 in patients with advanced cancer.